Collaborations & Alliances

Daiichi Sankyo, AgonO Enter Strategic Immuno-Onco Research Pact

AgonOx offers extensive expertise in validating the expression and function of immuno-oncology targets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Daiichi Sankyo Co., Ltd. has entered into a strategic collaboration with AgonOx, Inc. to develop an undisclosed immuno-oncology target. AgonOx is a privately-held biotechnology company developing novel immunotherapy drugs targeting key regulators of the immune response to cancer.   The companies will collaborate on preclinical development of the program, after which Daiichi Sankyo has an exclusive option to research, develop, manufacture and commercialize the program worldwide. Financial terms...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters